|
|
Lipocine Inc (NASDAQ: LPCN) |
|
Price: $3.6300
$-0.36 
-9.023%
|
| Day's High:
| $4.03
| Week Perf:
| 26.48 %
|
| Day's Low: |
$ 3.63 |
30 Day Perf: |
19.02 % |
| Volume (M): |
55 |
52 Wk High: |
$ 11.79 |
| Volume (M$): |
$ 201 |
52 Wk Avg: |
$4.82 |
| Open: |
$3.94 |
52 Wk Low: |
$2.68 |
|
|
| Market Capitalization (Millions $) |
21 |
| Shares
Outstanding (Millions) |
6 |
| Employees |
16 |
| Revenues (TTM) (Millions $) |
14 |
| Net Income (TTM) (Millions $) |
4 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Lipocine Inc
Lipocine Inc is a pharmaceutical company based in the United States that specializes in the development of oral drug delivery systems. The company focuses on creating innovative solutions to improve the absorption and bioavailability of orally administered drugs. Lipocine aims to address unmet medical needs through their proprietary technology platforms, which include methods to enhance solubility, enable controlled release, and improve overall drug performance. They primarily develop therapies in the areas of men's and women's health, with a particular focus on hormone replacement therapy and reducing the risk of cardiovascular disease.
Company Address: 675 Arapeen Drive Salt Lake City 84108 UT
Company Phone Number: 994-7383 Stock Exchange / Ticker: NASDAQ LPCN
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Stocks on the Move
Published Mon, Jul 22 2024 3:35 PM UTC
Lipocine Inc., a renowned biopharmaceutical company, has recently announced groundbreaking results from various studies, demonstrating the bioequivalence of its oral drug candidate, LPCN 1154, to the intravenous (IV) form of brexanolone. These results have the potential to revolutionize the treatment approach for postpartum depression (PPD) and other related conditions. In t...
|
| Stocks on the Move
Published Fri, Jun 28 2024 5:29 AM UTC
Lipocine Inc s Positive Study Results on BioequivalenceLipocine Inc., a pharmaceutical company, recently announced positive preliminary results from a pivotal pharmacokinetic study demonstrating the bioequivalence of its drug candidate, LPCN 1154. This milestone achievement showcases the potential of LPCN 1154 as an oral treatment option.In a study conducted by Lipocine, LP...
|
| Lipocine Inc
Lipocine Inc, a pharmaceutical company, recently announced an impressive revenue rise of 164.577% in the October to December 31, 2023 period, indicating potential growth prospects. However, a deep dive into the financials reveals a concerning trend of widening deficits and an overall negative performance. This article will explore the factors pushing Lipocine Inc towards a bearish outlook and delve into the implications of its financial performance.
Revenue Growth Masks Persistent Deficits:
While Lipocine Inc celebrated a substantial revenue improvement in the last quarter, it is important to take note of the widening deficit experienced by the company. Despite the positive revenue growth, the deficit expanded to $-0.44 million, underscoring the underlying financial struggles faced by the company.
|
| Lipocine Inc
Lipocine Inc, a pharmaceutical company traded on the NASDAQ exchange, has experienced a significant drop in stock value over the past five trading days. However, it is important to assess the company's performance in a broader context. This article will explore Lipocine Inc's recent financial results and evaluate how they might influence the company's future prospects.
1. Stock Performance:
Over the past five trading days, Lipocine Inc's stock has declined by -9.75%. Despite this short-term setback, the company has delivered an impressive year-to-date performance of 505.33%, indicating a strong overall growth trajectory. Furthermore, its current stock value is trading 9.7% above its 52-week average, suggesting positive market sentiment towards Lipocine Inc.
|
| Lipocine Inc
Lipocine Inc, a major pharmaceutical preparations company, has reported a disastrous financial performance for the quarter ending June 30, 2023. The company witnessed a significant decline in revenue, which dropped by a staggering -97.466% to only $0.03 million. Additionally, their net loss per share has swollen to $-0.68, a substantial increase from the same reporting period last year.
This gloomy financial report stands in sharp contrast to the rest of the major pharmaceutical preparations industry, which saw a 2.14% increase in revenue from the comparable reporting period a year ago. In comparison to the previous reporting period, Lipocine Inc's revenue has tumbled by -82.07% from $0.15 million to its current level. The net deficit for the financial time-frame ending June 30, 2023, amounted to $-3.549 million, surpassing the $-2.632 million loss recorded a year ago.
|
| Per Share |
Current |
| Earnings (TTM) |
0.62 $ |
| Revenues (TTM) |
2.48 $
|
| Cash Flow (TTM) |
0.09 $ |
| Cash |
3.72 $
|
| Book Value |
3.61 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.62 $
|
| Revenues (TTM) |
2.48 $ |
| Cash Flow (TTM) |
0.09 $ |
| Cash |
3.72 $
|
| Book Value |
3.61 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
6.13% 